JERUSALEM--(BUSINESS WIRE)-- Teva is pleased with the High Court’s decision today, which provides great clarity for both the drug industry as well as patients. This ruling reiterates that once the U.S. Food and Drug Administration approves a generic prescription drug as interchangeable to the brand, their labels must also be identical in all material respects. Accordingly, generic companies do not have the ability to influence labeling and related information and should not be held liable for failing to do so.
This is also a win for American consumers as they bear the ultimate burden of these lawsuits. The decision of the Supreme Court will help to alleviate unnecessary litigation.
Teva’s top priority is the quality of our products and the safety of our patients.
CONTACT:
Teva Pharmaceutical Industries Ltd.
Denise Bradley, 215-591-8974
[email protected]
KEYWORDS: United States North America New York Middle East Israel
INDUSTRY KEYWORDS: Health Public Policy/Government Courts Pharmaceutical FDA
MEDIA: